ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
General Health & Fitness
Health & Wellness
Tadalafil for the treatment of benign prostatic hyperplasia
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="madman" data-source="post: 142942" data-attributes="member: 13851"><p><a href="https://onlinelibrary.wiley.com/doi/pdf/10.1002/dta.1560" target="_blank"><span style="color: rgb(0, 0, 0)"><strong>ABSTRACT </strong></span></a></p><p></p><p><span style="color: rgb(184, 49, 47)"><strong>Introduction:</strong></span><span style="color: rgb(0, 0, 0)"> In men, lower urinary tract symptoms (LUTS) are primarily attributed to benign prostatic hyperplasia (BPH). Therapeutic options are targeted to relax prostate smooth muscle and/or reduce prostate enlargement. </span></p><p></p><p><span style="color: rgb(184, 49, 47)"><strong>Areas covered: </strong></span><span style="color: rgb(0, 0, 0)">This article reviews the major preclinical and clinical data on PDE5 inhibitors with a specific focus on tadalafil. It includes details of the role of the nitric oxide (NO)-cyclic guanosine monophosphate (cGMP) – PDE5 pathway in the LUT organs (bladder and prostate) in addition to the available data on tadalafil in patients with LUTS secondary to BPH with or without erectile dysfunction (ED). </span></p><p></p><p><span style="color: rgb(184, 49, 47)"><strong>Expert opinion: </strong></span><span style="color: rgb(0, 0, 0)">Preclinical and clinical data have clearly demonstrated that PDE5 inhibitors induce bladder and prostate relaxation, which contributes to the improvement seen in storage symptoms in both animal models of bladder and prostate hypercontractility. <strong>Tadalafil is effective both as a monotherapy and add-on therapy in patients with LUTS secondary to BPH</strong>. </span><span style="color: rgb(184, 49, 47)"><strong>Furthermore, as LUTS-BPH and ED are urological disorders that commonly coexist in aging men, tadalafil is more advantageous than α1- adrenoceptors and should be used as the first option. </strong></span><span style="color: rgb(0, 0, 0)"><strong>Tadalafil is a safe and tolerable therapy and unlike α1- adrenoceptors and 5-alpha reductase inhibitors, which can cause sexual dysfunctions, </strong></span><span style="color: rgb(184, 49, 47)"><strong>tadalafil improves sexual function.</strong></span> </p><p></p><p></p><p></p><p></p><p></p><p></p><p></p><p></p><p></p><p></p><p></p><p></p><p></p><p></p><p></p><p><strong>8. Conclusion</strong></p><p><strong><span style="color: rgb(184, 49, 47)">Tadalafil represents a well-tolerated and effective treatment option in men with LUTS-BPH with or without ED.</span></strong> As LUTS-BPH and ED can appear concomitantly in aging men, a drug that improves the signs and symptoms of both conditions is of therapeutic relevance.</p></blockquote><p></p>
[QUOTE="madman, post: 142942, member: 13851"] [URL='https://onlinelibrary.wiley.com/doi/pdf/10.1002/dta.1560'][COLOR=rgb(0, 0, 0)][B]ABSTRACT [/B][/COLOR][/URL] [COLOR=rgb(184, 49, 47)][B]Introduction:[/B][/COLOR][COLOR=rgb(0, 0, 0)] In men, lower urinary tract symptoms (LUTS) are primarily attributed to benign prostatic hyperplasia (BPH). Therapeutic options are targeted to relax prostate smooth muscle and/or reduce prostate enlargement. [/COLOR] [COLOR=rgb(184, 49, 47)][B]Areas covered: [/B][/COLOR][COLOR=rgb(0, 0, 0)]This article reviews the major preclinical and clinical data on PDE5 inhibitors with a specific focus on tadalafil. It includes details of the role of the nitric oxide (NO)-cyclic guanosine monophosphate (cGMP) – PDE5 pathway in the LUT organs (bladder and prostate) in addition to the available data on tadalafil in patients with LUTS secondary to BPH with or without erectile dysfunction (ED). [/COLOR] [COLOR=rgb(184, 49, 47)][B]Expert opinion: [/B][/COLOR][COLOR=rgb(0, 0, 0)]Preclinical and clinical data have clearly demonstrated that PDE5 inhibitors induce bladder and prostate relaxation, which contributes to the improvement seen in storage symptoms in both animal models of bladder and prostate hypercontractility. [B]Tadalafil is effective both as a monotherapy and add-on therapy in patients with LUTS secondary to BPH[/B]. [/COLOR][COLOR=rgb(184, 49, 47)][B]Furthermore, as LUTS-BPH and ED are urological disorders that commonly coexist in aging men, tadalafil is more advantageous than α1- adrenoceptors and should be used as the first option. [/B][/COLOR][COLOR=rgb(0, 0, 0)][B]Tadalafil is a safe and tolerable therapy and unlike α1- adrenoceptors and 5-alpha reductase inhibitors, which can cause sexual dysfunctions, [/B][/COLOR][COLOR=rgb(184, 49, 47)][B]tadalafil improves sexual function.[/B][/COLOR][COLOR=rgb(0, 0, 0)][B] [/B][/COLOR] [B]8. Conclusion [COLOR=rgb(184, 49, 47)]Tadalafil represents a well-tolerated and effective treatment option in men with LUTS-BPH with or without ED.[/COLOR][/B] As LUTS-BPH and ED can appear concomitantly in aging men, a drug that improves the signs and symptoms of both conditions is of therapeutic relevance. [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
General Health & Fitness
Health & Wellness
Tadalafil for the treatment of benign prostatic hyperplasia
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top